



June 23, 2022

«Member\_First\_Name» «Member\_Last\_Name»  
«Member\_Address\_1»  
«Member\_Address\_2»  
«City», «State\_» «Zip\_Code»

Dear University of Arkansas System Member,

**MedImpact Healthcare Systems, Inc.**, (MedImpact) on behalf of the University of Arkansas System Health Plan, will be implementing a change to the prescription benefit plan that affects you. **Please continue to read this entire letter.**

**Effective July 1, 2022**, a prior authorization will be required for **Descovy** under the prescription benefit plan. You are receiving this letter because our records indicate you had a prescription filled for **Descovy** within the last 120 days.

The Plan will continue to cover your prescription without a prior authorization for **Descovy** through **September 30, 2022**, to allow sufficient time for you to discuss this change with your physician. Below are formulary alternatives that have been determined to be clinically equivalent to Descovy that do not require a prior authorization:

**Generic Truvada (EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (TDF))**

Included with this letter is the Plan's prior authorization criteria document which you may provide to your physician for reference of this new guideline. Please ask your physician to contact EBRx at (833) 650-0475 if the current prescription is being used for treatment rather than prophylactically.

Benefits for all services are subject to terms, conditions, and eligibility as outlined in the benefit documentation in effect at the time services are provided.

If you have questions, please contact MedImpact Healthcare Systems, Inc. at 1-800-788-2949.

Sincerely,

MedImpact and the University of Arkansas Pharmacy Advisory Committee

*The University of Arkansas' prescription drug formulary, administered by MedImpact, is maintained by the University of Arkansas System's Pharmacy Advisory Committee. The Pharmacy Advisory Committee is composed of both faculty and clinical pharmacists, who advise the Committee on the most recent medical research results. The recommendations by the committee are based on the latest available evidence-based studies.*